According to the GNBTP S-1 they are in advanced "t
Post# of 36537
Page 52 GNBTP S-1:
The funding for the development of a vaccine of SARS-CoV-2 virus is in advanced discussions and currently expected that the development costs will be borne by the U.S. and foreign government agencies and without additional external funding, Generex will not pursue these projects.
https://www.sec.gov/Archives/edgar/data/10597...forms1.htm